Abstract 4288
Background
Genomic profiling of blood-derived circulating tumour DNA (ctDNA) which is considered as a minimally invasive biopsy, has several potential applications in the management of ovarian cancer, including selection of targeted therapy, drug resistance prediction and the evaluation of treatment response. Therefore, we conducted this study to characterize genomic alterations (GA) in ctDNA from patients with ovarian cancer and compare GA detected in ctDNA with those detected in tissue databases.
Methods
Hybrid capture-based next generation sequencing (NGS) genomic profiling of 150 genes was performed on ctNDA from 76 patients with ovarian cancer in a CAP-accredited laboratory. The GA detected in ctDNA were compared with the 3D Med tissue database tested by NGS (N = 260) and TCGA database tested by whole-exon sequencing (N = 587). The fraction of ctDNA was estimated using the maximum somatic allele frequency (MSAF). GAs including single nucleotide variation (SNV), insertions/deletions, copy number variations, gene rearrangement and fusions were assessed. Germline alterations were excluded.
Results
89.5% (68/76) of patients (median age 57) detected ≥1 GA in ctDNA. Frequently altered genes detected in ctDNA for SNV were TP53 (52.6%), AR (11.8%), KRAS (9.2%), NOTCH2 (6.6%) and PIK3CA (5.3%) compared to 3D Med tissue database (median age 55) including 260 samples with TP53 (74.2%), AR (6.9%), KRAS (24.6%) NOTCH2 (11.5%) and PIK3CA (3.8%). In TCGA database including 587 patients with early stage diseases, the frequencies of the commonly altered genes detected in ctDNA were largely different with TP53 (65.9%), AR (1.0%), KRAS (1.0%), NOTCH2 (1.2%) and PIK3CA (2.6%). Alterations in five DNA damage repair associated-genes including BRCA1, BRCA2, ATM, ATR, RAD50 and CHEK2 were detected in 14.5% (11/76) of patients in ctDNA database compared to 19.2% (50/260) of patients in 3D Med tissue database and 12.6% (74/587) of patients in TCGA database.
Conclusions
Our results suggest that genomic profiling of ctDNA could detected GAs in a significant subset of patients with ovarian cancer. Hybrid capture- NGS based ctDNA liquid biopsy has the potential capability to serve as an alternative to tissue biopsy and further studies are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NanJing GaoChun People’s Hospital.
Funding
Has not received any funding.
Disclosure
Y. Zhang: Full / Part-time employment: 3D Medicines Inc. S. Cai: Full / Part-time employment: 3D Medicines Inc. All other authors have declared no conflicts of interest.
Resources from the same session
5612 - Evaluation of germ line mutational status among women with triple-negative breast cancer in Russia
Presenter: Elena Shagimardanova
Session: Poster Display session 2
Resources:
Abstract
4142 - Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)
Presenter: Alberto Ocaña
Session: Poster Display session 2
Resources:
Abstract
1733 - Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer
Presenter: Jianfei Fu
Session: Poster Display session 2
Resources:
Abstract
1978 - A Nomogram to Predict Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Blood Indicators
Presenter: Fanrong Zhang
Session: Poster Display session 2
Resources:
Abstract
3062 - Identification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells
Presenter: Sujin Yang
Session: Poster Display session 2
Resources:
Abstract
5274 - Expression of X-linked Inhibitor of Apoptosis Protein (XIAP) and its Association with Clinicopathological Parameters in Invasive Breast Cancers
Presenter: Gayathri Devi
Session: Poster Display session 2
Resources:
Abstract
1324 - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients
Presenter: Soo Youn Bae
Session: Poster Display session 2
Resources:
Abstract
4877 - Correlation of clinical and pathological features with the tumour microenvironment in DCIS. An institutional experience
Presenter: Ann Eapen
Session: Poster Display session 2
Resources:
Abstract
2471 - Correlation between radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer and pathologic complete response and their impact in recurrence-free survival
Presenter: Ariadna Gasol Cudos
Session: Poster Display session 2
Resources:
Abstract
2632 - Ring-like uptake appearance on dedicated breast positron emission tomography before chemotherapy predicts outcome of neoadjuvant chemotherapy in breast cancer
Presenter: Norio Masumoto
Session: Poster Display session 2
Resources:
Abstract